Lilly Details Phase 3 Retatrutide TRIUMPH-1 Results

Efficacy results from the Phase 3 TRIUMPH-1 trial of retatrutide were presented at the 2026 American Diabetes Association Scientific Sessions.

A medical breakthrough is redefining what is possible for weight management. On June 6, 2026, Eli Lilly and Company presented Phase 3 results for retatrutide at the American Diabetes Association (ADA) 2026 Scientific Sessions. This experimental drug is a triple hormone receptor agonist, meaning it mimics three natural gut hormones—GLP-1, GIP, and glucagon—to suppress appetite and accelerate metabolism. The TRIUMPH-1 trial showed that patients on the highest dose (12 mg) achieved an astonishing average weight loss of 30.3% at 104 weeks.

What Is Retatrutide and How Does the Triple Agonist Work?

Retatrutide is a single molecule that acts as a triple hormone mimic, targeting three separate receptors in your body: GLP-1, GIP, and glucagon. While existing weight-loss drugs target one or two of these pathways to curb appetite and improve blood sugar, retatrutide adds a third target: glucagon. This triple-action approach is designed to control hunger, improve insulin response, and actively boost your body's energy expenditure. By targeting all three pathways at once, researchers hope to deliver unparalleled weight-loss results.

The GLP-1 and GIP parts of retatrutide work in your brain to signal fullness and slow down digestion, helping you eat less without feeling deprived. Meanwhile, the glucagon component prompts your body to burn more energy and break down stored fat, even when you are eating fewer calories. This preventing of a metabolic slowdown is key to achieving dramatic, long-lasting weight loss. Because retatrutide engages three powerful hormone systems at once, patients must increase their doses slowly to help prevent side effects.

What Were the Key Efficacy Findings in the TRIUMPH-1 Trial?

The Phase 3 TRIUMPH-1 trial evaluated how weekly injections of retatrutide (4 mg, 9 mg, and 12 mg) compared to a placebo in adults with obesity or overweight. All participants had at least one weight-related health condition, excluding diabetes. Researchers tracked their weight loss progress over an 80-week period to measure the drug's true effectiveness. This study provides a clear picture of what patients can expect from this therapy.

The detailed findings presented at the ADA conference show that retatrutide delivered remarkable, dose-dependent weight loss. At week 80, patients achieved these outstanding average weight reductions:

• 12 mg Dose: Patients lost an average of 28.3% of their weight (about 70.3 pounds).
• 9 mg Dose: Patients lost an average of 25.9% of their weight (about 64.4 pounds).
• 4 mg Dose: Patients lost an average of 19.0% of their weight (about 47.2 pounds).
• Placebo Group: Patients lost a minimal average of 1.6% of their weight.

These figures demonstrate that retatrutide provides powerful metabolic support, helping patients shed substantial amounts of excess weight.

The trial also measured the percentage of patients reaching life-changing weight loss milestones. In the highest-dose group, a staggering 45.3% of patients lost 30% or more of their body weight, matching results normally seen only after surgery. Even better, 65.3% of patients in this group dropped their BMI below 30, meaning they were no longer clinically classified as obese. These surgical-like results represent a major turning point for patients dealing with severe weight issues.

How Did the Extended 104-Week Results Compare for Higher BMI Patients?

Obesity is a chronic condition, meaning long-term weight maintenance is critical for patients. To see how retatrutide performs over time, researchers followed a group of patients with a BMI of 35 or higher for 104 weeks. This group represents patients with severe obesity who often find weight loss particularly challenging due to metabolic resistance. Tracking their progress for two years helps ensure that the weight loss is both safe and durable.

The long-term results show that weight loss did not stop at the one-year mark. By week 104, patients on the 12 mg dose achieved an unprecedented average weight loss of 30.3%, which equals about 85 pounds. This demonstrates that extended therapy can keep working to help you reach and maintain your health goals. For patients, this represents a steady and durable path toward lasting wellness.

Retatrutide also delivered comprehensive health benefits beyond the scale. Patients lost excess body fat while successfully preserving their lean muscle tissue. They also saw significant drops in blood pressure, insulin, cholesterol, and liver fat levels. These improvements mean that losing 30% of your weight can help reverse chronic conditions like high blood pressure and fatty liver disease.

What Safety Signals and Discontinuation Rates Were Observed in the Study?

Understanding a drug's side effects is essential when choosing a treatment plan. In the trial, retatrutide's safety was similar to other gut-hormone weight-loss medications. The most common side effects were gastrointestinal, mostly occurring as patients slowly increased their dose. Fortunately, these symptoms were temporary and generally faded over time.

While most side effects were manageable, the trial documented the following rates for stomach-related symptoms compared to placebo:

• Nausea: Affected 28.6% to 42.4% of patients on retatrutide (versus 14.8% on placebo).
• Diarrhea: Affected 25.2% to 32.0% of patients on retatrutide (versus 13.5% on placebo).
• Constipation: Affected 23.8% to 26.1% of patients on retatrutide (versus 10.9% on placebo).
• Vomiting: Affected 10.6% to 25.3% of patients on retatrutide (versus 4.8% on placebo).

Most of these symptoms were reported as mild to moderate in severity, showing that the drug's safety profile remains acceptable for clinical use.

A small percentage of patients chose to stop taking the medication due to side effects. Discontinuation rates ranged from 4.1% on the 4 mg dose to 11.3% on the 12 mg dose, compared to 4.9% in the placebo group. This shows that the majority of patients were able to stay on the medication successfully. Your healthcare provider can help customize your dosing to keep you comfortable.

Researchers also monitored heart rate changes and skin sensations during the trial. Some patients experienced a temporary increase in heart rate during dose increases, which later returned to normal. Others reported mild-to-moderate dysesthesia, which refers to unusual skin sensitivity like tingling or numbness. This affected 5.1% to 12.5% of patients but was mild and rarely caused anyone to stop the study.

When Can Patients and Providers Expect Regulatory Submission and Approval?

Lilly plans to submit retatrutide for FDA approval in the fourth quarter of 2026. If the regulatory review goes smoothly, this groundbreaking treatment could become available to patients by late 2027. This timeline represents a major milestone for patients looking forward to next-generation options. Doctors are already preparing to integrate this medication into their clinical toolkits.

While waiting for retatrutide, you can still access highly effective approved options today. You can discuss joining a semaglutide treatment program or starting tirzepatide options with a qualified physician. To take your first step, you can check if you qualify online. You can also view current pricing details to find a weight loss option that fits your financial goals.

Remember that retatrutide is still undergoing clinical testing and is not yet available for public use. Researchers are continuing to evaluate its safety and long-term benefits in patients with other health conditions, such as sleep apnea and osteoarthritis. In the meantime, work with your healthcare provider to build a personalized care plan using current therapies. A combination of approved treatments and healthy lifestyle adjustments remains the best path forward.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.